Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.
Yiqun Du(Shandong University), Jiangfeng Li(First Affiliated Hospital Zhejiang University), Yongmin Yang, Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), David Sommerhalder(Texas Oncology), Benjie Wang(Qilu Hospital of Shandong University), Meili Sun(Jinan Central Hospital), Chao Li(Eli Lilly (United States)), Lian Liu(Qilu Hospital of Shandong University), Huan Zhou(Bengbu Medical College), Jian Zhang(Fudan University Shanghai Cancer Center), Zhen Wang(Huanghuai University), Xiumin Li(New York Medical College), Yawen Zheng(Tianjin University), Zhenyuan Gao(First Affiliated Hospital of Bengbu Medical College), Xiangyang Zhu(Shanghai Artificial Intelligence Laboratory), Yang Yang(CSPC Pharmaceutical Group), Qing Wen(Jinan Central Hospital)
Cited by 7
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
|Cancer Discovery|2017|418
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276